MedTrace Logo

Vaccine Prevention of Rabies Adopts 4-shot Immunization Method

NCT05549908 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1800

Last updated 2024-03-13

No results posted yet for this study

Summary

A phase III clinical trial to evaluate the immunogenicity and safety of freeze-dried human rabies vaccine (Vero cell) developed by Changchun Zhuoyi Biological Co., Ltd. inoculated in a 4-dose procedure (2-1-1)

Conditions

  • Rabies Human
  • Antibody Titer

Interventions

BIOLOGICAL

rabies vaccine

The subjects were vaccinated with rabies vaccines with different immunization procedures, and the safety and immunogenicity were compared

Sponsors & Collaborators

  • Changchun Zhuoyi Biological Co., Ltd

    lead OTHER

Principal Investigators

  • Li Miao, Dr · Changchun Zhuoyi Biological Co., Ltd

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-22
Primary Completion
2021-10-31
Completion
2023-04-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05549908 on ClinicalTrials.gov